Fungal vaccines: real progress from real challenges (Q37067893)

18 August 2017

1 reference

title

Fungal vaccines: real progress from real challenges (English)

1 reference

18 August 2017

1

Antonio Cassone

1 reference

18 August 2017

language of work or name

1 reference

1 February 2008

1 reference

Lancet Infectious Diseases

18 August 2017

published in

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

114-124

1 reference

Polysaccharide-containing conjugate vaccines for fungal diseases.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A novel glyco-conjugate vaccine against fungal pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Coccidioidomycosis: host response and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Advances in combating fungal diseases: vaccines on the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Towards a vaccine for Cryptococcus neoformans: principles and caveats.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Preventative and therapeutic vaccines for fungal infections: from concept to implementation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Prospects of vaccines for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Development of a vaccine for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Vaccinate against aspergillosis! A call to arms of the immune system.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Induced humoral immunity and vaccination against major human fungal pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A vaccine against coccidioidomycosis is justified and attainable

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Is a vaccine needed against Candida albicans?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Prospects for development of vaccines against fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Fungal heat-shock proteins in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Passive antibody therapy for infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Recombinant antibodies: a natural partner in combinatorial antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Dendritic cell-based vaccination against opportunistic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Immunity to fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

The third age of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Medicine. The intangible value of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Risk factors for hospital-acquired candidemia. A matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Major trends in the microbial etiology of nosocomial infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Emerging fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Epidemiology of invasive candidiasis: a persistent public health problem

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Invasive candidiasis in immunocompromised hospitalized patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Current issues in critical care of the human immunodeficiency virus-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Invasive candidiasis in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

1 reference

7 January 2021

Echinocandin antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

The fungal cell wall as a drug target

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Emerging azole antifungals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Managing infections in the immunocompromised patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Immunoparalysis as a cause for invasive aspergillosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

The immune response to fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Role for dendritic cells in immunoregulation during experimental vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Interactions of Toll-like receptors with fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Fungal β-Glucans and Mammalian Immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

The interaction of human dendritic cells with yeast and germ-tube forms of Candida albicans leads to efficient fungal processing, dendritic cell maturation, and acquisition of a Th1 response-promoting function.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Phagocytosis of Aspergillus fumigatus conidia by murine macrophages involves recognition by the dectin-1 beta-glucan receptor and Toll-like receptor 2

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Direct antimicrobial activity of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Interleukin-10 production by effector T cells: Th1 cells show self control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Fungal morphogenesis and host invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Host-microbe interactions: fungi invasive human fungal opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Candida albicans yeast and germ tube forms interfere differently with human monocyte differentiation into dendritic cells: a novel dimorphism-dependent mechanism to escape the host's immune response.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A drug-sensitive genetic network masks fungi from the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Defective induction of interleukin-12 in human monocytes by germ-tube forms of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Mycobacterium tuberculosis subverts the differentiation of human monocytes into dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

CD4+ T cell-independent DNA vaccination against opportunistic infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Engineered antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Role of anti-beta-glucan antibody in host defense against fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Candidacidal activity of a monoclonal antibody that binds with glycosyl moieties of proteins of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Recombinant single-chain anti-idiotypic antibody: an effective fungal beta-1,3-glucan synthase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Defining criteria for anti-mannan antibodies to protect against candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Identification of a protective antigen of Coccidioides immitis by expression library immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

DNA-based vaccination against murine paracoccidioidomycosis using the gp43 gene from paracoccidioides brasiliensis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

T cell vaccination in mice with invasive pulmonary aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

The 65 kDa mannoprotein gene of Candida albicans encodes a putative beta-glucanase adhesin required for hyphal morphogenesis and experimental pathogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Antibody-guided alpha radiation effectively damages fungal biofilms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

From Pasteur to genomics: progress and challenges in infectious diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Enhanced defense against Pneumocystis carinii mediated by a novel dectin-1 receptor Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

An arthroconidial-spherule antigen of Coccidioides immitis: differential expression during in vitro fungal development and evidence for humoral response in humans after infection or vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

Prospects for and barriers to a fungal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970016-1

7 January 2021

10.1016/S1473-3099(08)70016-1

Identifiers

DOI

1 reference

18 August 2017

1 reference